title: Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.
abstract: OBJECTIVE
  Burkitt lymphoma (BL) is a rare and aggressive form of B-cell lymphoma that is curable using intensive chemotherapy. Obtaining a complete response (CR) at the end of induction chemotherapy is a major prognostic factor. This study retrospectively evaluates the potential impact of (18)FDG-PET in the management of children with BL after induction chemotherapy, and the prognostic performance of the Deauville criteria.
  
  
  METHODS
  Nineteen children with BL treated according to the French LMB2001 protocol between 2005 and 2012 were included. (18)FDG-PET and conventional imaging (CI) were performed after induction chemotherapy to confirm CR. (18)FDG-PET was interpreted according to Deauville criteria with follow-up and/or histology as the gold standard.
  
  
  RESULTS
  (18)FDG-PET was negative in 15 cases, in agreement with CI in 9/15 cases. The six discordant cases confirmed to be negative by histology, were considered as true negative for (18)FDG-PET. Negative predictive value (NPV) of CI and (18)FDG-PET were 73 and 93%, respectively. The 5-year progression-free survival (PFS) was significantly higher in patients with negative (18)FDG-PET than those with positive (18)FDG-PET (p = 0.011).
  
  
  CONCLUSIONS
  (18)FDG-PET interpreted using Deauville criteria can help confirm CR at the end of induction chemotherapy, with a prognostic impact on 5-year PFS. Its high NPV could limit the use of residual mass biopsy. Given the small size of our population, these results need to be confirmed by future prospective studies on a larger population.
authors.affiliation: Department of Nuclear Medicine, University Hospital , Nantes , France.
authors.forename: Clément
authors.initials: C
authors.lastname: Bailly
authors.affiliation: Department of Nuclear Medicine, University Hospital , Nantes , France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Eugène
authors.affiliation: Department of Pediatric Oncology, University Hospital , Nantes , France.
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Couec
authors.affiliation: Department of Pediatric Oncology, University Hospital , Nantes , France.
authors.forename: Marion
authors.initials: M
authors.lastname: Strullu
authors.affiliation: Department of Radiology, University Hospital , Nantes , France ; U892, CNRS UMR 6299, CRCNA, INSERM , Nantes , France.
authors.forename: Eric
authors.initials: E
authors.lastname: Frampas
authors.affiliation: U892, CNRS UMR 6299, CRCNA, INSERM , Nantes , France ; Department of Biometrics, Cancer Center ICO René Gauducheau , Nantes , France.
authors.forename: Loïc
authors.initials: L
authors.lastname: Campion
authors.affiliation: Department of Nuclear Medicine, University Hospital , Nantes , France ; U892, CNRS UMR 6299, CRCNA, INSERM , Nantes , France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.affiliation: Department of Nuclear Medicine, University Hospital , Nantes , France ; U892, CNRS UMR 6299, CRCNA, INSERM , Nantes , France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Bodet-Milin
keywords: Burkitt lymphoma; Deauville criteria; FDG-PET; induction chemotherapy; pediatric lymphoma